CORDIS
EU research results

CORDIS

English EN
Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling

Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling

Objective

The airways diseases asthma and chronic obstructive pulmonary disease affect over 400 million people world-wide and cause considerable morbidity and mortality. Airways disease costs the European Union in excess of €56 billion per annum. Current therapies are inadequate and we do not have sufficient tools to predict disease progression or response to current or future therapies. Our consortium, Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM), brings together the exisiting clinical consortia (EvA FP7, U-BIOPRED IMI and BTS Severe Asthma), and expertise in physiology, radiology, image analysis, bioengineering, data harmonization, data security and ethics, computational modeling and systems biology. We shall develop an integrated multi-scale model building upon existing models. This airway model will be comprised of an integrated 'micro-scale' and 'macro-scale' airway model informed and validated by 'omic data and ex vivo models at the genome-transcriptome-cell-tissue scale and by CT and functional MRI imaging coupled to detailed physiology at the tissue-organ scale utilising Europe's largest airway disease cohort. Validation will be undertaken cross-sectionally, following interventions and after longitudinal follow-up to incorporate both spatial and temporal dimensions. AirPROM has a comprehensive data management platform and a well-developed ethico-legal framework. Critically, AirPROM has an extensive exploitation plan, involving at its inception and throughout its evolution those that will 'develop' and 'use' the technologies emerging from this project. AirPROM therefore will bridge the critical gaps in our clinical management of airways disease, by providing validated models to predict disease progression and response to treatment and the platform to translate these patient-specific tools, so as to pave the way to improved, personalised management of airways disease.

Coordinator

UNIVERSITY OF LEICESTER

Address

University Road
Le1 7rh Leicester

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 120 019

Administrative Contact

Marie Adams (Ms.)

Participants (39)

Sort alphabetically

Sort by EU Contribution

Expand all

FluidDA nv

Belgium

EU Contribution

€ 578 631

MATERIALISE NV

Belgium

EU Contribution

€ 556 500

BIOSCI CONSULTING

Belgium

EU Contribution

€ 517 638

EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING

Belgium

EU Contribution

€ 81 360

EUROPEAN RESPIRATORY SOCIETY

Switzerland

EU Contribution

€ 112 680

BIOMAX INFORMATICS AG

Germany

EU Contribution

€ 653 360

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 72 337

OBJET GEOMETRIES GMBH

Germany

EU Contribution

€ 30 318

FUNDACIO PARC CIENTIFIC DE BARCELONA

Spain

EU Contribution

€ 49 320

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 410 080

UNIVERSITE DE LA MEDITERRANEE D'AIX-MARSEILLE II

France

EU Contribution

€ 38 000

INSTITUT MINES-TELECOM

France

EU Contribution

€ 535 799

UNIVERSITE D'AIX MARSEILLE

France

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 23 553

ORSZAGOS KORANYI TBE ES PULMONOLOGIAI INTEZET

Hungary

EU Contribution

€ 53 000

SEMMELWEIS EGYETEM

Hungary

EU Contribution

€ 20 500

UNIVERSITA DEGLI STUDI DI CATANIA

Italy

EU Contribution

€ 24 800

UNIVERSITA DEGLI STUDI DI FERRARA

Italy

EU Contribution

€ 54 998

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 345 300

INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK

Poland

EU Contribution

€ 378 640

INSTYTUT GRUZLICY I CHOROB PLUC

Poland

EU Contribution

€ 36 400

VASTRA GOTALANDS LANS LANDSTING

Sweden

EU Contribution

€ 66 800

UMEA UNIVERSITET

Sweden

EU Contribution

€ 17 500

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 18 220

GREATER GLASGOW HEALTH BOARD

United Kingdom

EU Contribution

€ 50 760

HEART OF ENGLAND NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 30 002

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 135 800

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 27 852

UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 872

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 1 587 385

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 48 800

EUROPEAN LUNG FOUNDATION

United Kingdom

EU Contribution

€ 98 760

ANSYS UK LIMITED

United Kingdom

EU Contribution

€ 352 112

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 008 216

THE UNIVERSITY OF NOTTINGHAM

United Kingdom

EU Contribution

€ 792 818

THE UNIVERSITY OF WARWICK

United Kingdom

EU Contribution

€ 711 504

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 60 200

ANSYS GERMANY GMBH

Germany

EU Contribution

€ 6 180

ANSYS FRANCE SAS

France

EU Contribution

€ 6 180

Project information

Grant agreement ID: 270194

Status

Closed project

  • Start date

    1 March 2011

  • End date

    30 June 2016

Funded under:

FP7-ICT

  • Overall budget:

    € 15 535 205

  • EU contribution

    € 11 713 194

Coordinated by:

UNIVERSITY OF LEICESTER

United Kingdom